Anebulo Pharmaceuticals Inc

NASDAQ ANEB

Data sourced from iex and EODHD
Download Data

Anebulo Pharmaceuticals Inc Enterprise Value (EV) on June 03, 2024

Anebulo Pharmaceuticals Inc Enterprise Value (EV) is NA on June 03, 2024, a NA change year over year. Enterprise Value is a measure of a company's total value, including both its equity and debt. It represents the theoretical takeover price of a company and is often used in valuation methods. Enterprise value is calculated as the sum of a company's market capitalization, total debt, and subtracting its cash and short-term investments.
  • Anebulo Pharmaceuticals Inc 52-week high Enterprise Value (EV) is NA on June 03, 2024, which is NA below the current Enterprise Value (EV).
  • Anebulo Pharmaceuticals Inc 52-week low Enterprise Value (EV) is NA on June 03, 2024, which is NA below the current Enterprise Value (EV).
  • Anebulo Pharmaceuticals Inc average Enterprise Value (EV) for the last 52 weeks is NA.
NASDAQ: ANEB

Anebulo Pharmaceuticals Inc

CEO Dr. Joseph F. Lawler M.D., Ph.D.
IPO Date May 7, 2021
Location United States
Headquarters 1415 Ranch Road 620 South, Lakeway, TX, United States, 78734
Employees 2
Sector Healthcare
Industry Biotechnology
Description

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Similar companies

ADAG

Adagene Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

AVTE

Aerovate Therapeutics Inc

NA

NA

ANTX

AN2 Therapeutics Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email